Skip to main content
Article thumbnail
Location of Repository

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR-γ Agonist Lowers Triglyceride Independently of PPAR-α Activation

By Apurva Chandalia, Holly J. Clarke, L. Edward Clemens, Bindu Pandey, Vic Vicena, Paul Lee, Brian E. Lavan and Francine M. Gregoire


MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR-γ agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with the TZDs. Interestingly MBX-102 also displays pronounced triglyceride lowering in preclinical rodent models and in humans. Although in vitro reporter gene studies indicated that MBX-102 acid is a highly selective PPAR-γ agonist that lacks PPAR-α activity, we sought to determine if PPAR-α activation in vivo could possibly contribute to the triglyceride lowering abilities of MBX-102. In vivo studies using ZDF and ZF rats demonstrated that MBX-102 lowered plasma triglycerides. However in ZF rats, MBX-102 had no effect on liver weight or on hepatic expression levels of PPAR-α target genes. Further in vitro studies in primary human hepatocytes supported these findings. Finally, the ability of MBX-102 to lower triglycerides was maintained in PPAR-α knockout mice, unambiguously establishing that the triglyceride lowering effect of MBX-102 is PPAR-α independent. The in vivo lipid lowering abilities of MBX-102 are therefore mediated by an alternate mechanism which is yet to be determined

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier:
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    1. (1975). A r o n o w ,M .D .V i c a r i o ,K .M o o r t h y ,J .K i n g ,M .V a w t e r
    2. (1976). A two year crossover therapeutic12 PPAR Research trial with halofenate and clofibrate,”
    3. (2000). Activation of human peroxisome proliferator-activated receptor (PPAR)subtypesbypioglitazone,”BiochemicalandBiophysical
    4. (2004). Bone is a target for the antidiabetic compound rosiglitazone,”
    5. (2008). c h m u t h ,Y .J .J i a n g ,P .M .E l i a s ,a n dK .R .F e i n g o l d , “Thematic review series: skin lipids. Peroxisome proliferatoractivatedreceptorsandliverXreceptorsinepidermalbiology,”
    6. (1969). Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen,”
    7. (1973). Effect of halofenate on serum uric acid,”
    8. (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England
    9. (2003). Effect of thiazolidinediones on body weight in patients with diabetes mellitus,”
    10. (1978). Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia,”
    11. (2004). Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone),”
    12. (2007). Evolution of peroxisome proliferator-activated receptor agonists,”
    13. (2008). Fibrate therapy: an update,”
    14. (1995). Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates,”
    15. (2006). From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,”
    16. (2005). G o l d b e r g ,D .M .K e n d a l l ,M .A .D e e g ,e ta l . ,“ A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care,
    17. Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat,”JournalofLipidResearch,vol.17,no.2,pp.156–166,1976.
    18. (2006). Halofenate is a selective peroxisome proliferator-activated receptorγ modulator with antidiabetic activity,”
    19. (2006). International Union of Pharmacology.
    20. (1977). K r u t ,H .C .S e f t e l ,a n dB .I .J o ffe, “Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia,”
    21. (2007). Lipids, lipoproteins, and peroxisome proliferatoractivated receptor-δ,” TheAmericanJournal ofCardiology,
    22. (2008). M a d r a z oa n dD .P .K e l l y ,“ T h eP P A Rt r i o :r e g u l a t o r so f myocardial energy metabolism in health and disease,”
    23. (2006). M¨ u l l e r ,a n dS .K e r s t e n ,“ P e r o x i -some proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression,”
    24. (1998). Mechanism of action of fibrates on lipid and lipoprotein metabolism,”
    25. (2003). Mechanisms of actions of statins and fibrates,”
    26. (2007). Molecular basis of selective PPARγ modulation for the treatment of type 2
    27. (2007). Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,”
    28. o s e n s t o c k ,F .F l o r e s - L o z a n o ,S .S c h a r t z ,G .G o n z a l e z
    29. (1976). One year trials with halofenate,clofibrate,andplacebo,”ClinicalPharmacologyand Therapeutics,
    30. (2008). P e t e r s ,H .E .H o l l i n g s h e a d ,a n dF .J .G o n z a l e z ,“ R o l eo f peroxisome-proliferator-activated receptor β/δ (PPARβ/δ)i n gastrointestinal tract function and disease,”
    31. (2008). Peroxisome proliferator activated receptors and lipoprotein metabolism,”
    32. (2003). Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control,”
    33. (2007). Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,”
    34. (2007). Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal
    35. (2008). Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-tohead randomized clinical studies,”
    36. (2006). Pioglitazone: a review of its use
    37. (2008). R e i l l ya n dC .
    38. (2008). Renal and vascular mechanisms of thiazolidinedione-induced fluid retention,”
    39. (2007). Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,”
    40. (2007). S 26948: a new specific peroxisome proliferator-activated receptor γ modulator with potent antidiabetes and antiatherogenic effects,”
    41. (2007). Safety issues and prospects for future generations ofPPAR
    42. (2006). Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases,”
    43. (2007). Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects,”
    44. (2008). Skeletal consequences of thiazolidinedione therapy,”
    45. (2005). t u m v o l l ,B .J .G o l d s t e i n ,a n dT .W .v a nH a e f t e n ,“ T y p e2 diabetes: principles of pathogenesis and therapy,”
    46. (2005). The clinical significance of PPAR gamma agonism,”
    47. (2008). The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities,”
    48. (2007). The next generation of PPAR drugs: do we have the tools to find them?”
    49. (1996). The structureactivity relationship between peroxisome proliferatoractivated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,”
    50. (2004). Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Diabetes Care,v o l .2 7 ,n o .1 ,p p .
    51. (2008). TZDs and bone: a review of the recent clinical evidence,”
    52. (2008). Use of thiazolidinediones and fracture risk,”

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.